Sign in
Protocol U: Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involv
Raj K. Maturi, MD
Updates from the Field
2017
Is It Necessary to Peel Internal Limiting Membrane in Diabetic Vitrectomy
Stanley Chang, MD
2022
New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Annual Meeting Talks
Category: Technology